Sumiカジノ シークレット 入金 不要mo Chemical カジノ シークレット 入金 不要 Construct a New Manufacturing Plant for Active Pharmaceutical Ingredients and Intermediates for Small Molecule Drugs at Oita Works in Japan
Supplying a variety of high-quality products as a leading CDMO in Japan

Mar. 30, 2022

Sumiカジノ シークレット 入金 不要mo Chemical Co., Ltd. will construct a new manufacturing plant for active pharmaceutical ingredients (APIs) and intermediates for small molecule drugs at its Oita Works (Oita City, Oita Prefecture, Japan). This project is カジノ シークレット 入金 不要 enhance the Company’s capacity カジノ シークレット 入金 不要 supply a variety of high-quality APIs and intermediates in response カジノ シークレット 入金 不要 the increasing demand for small molecule drugs. The new plant is scheduled カジノ シークレット 入金 不要 come on stream in September 2024.

Pharmaceuticals with low molecular weight, called small molecule drugs^*1, are produced by chemical synthesis. Leveraging the strengths in advanced organic synthesis technology and process engineering it has refined as a diversified chemical company, Sumiカジノ シークレット 入金 不要mo Chemical engages in the contract manufacturing of small molecule drug APIs and intermediates for pharmaceutical companies in its Contract Development and Manufacturing Organization (“CDMO”) business and also produces and supplies APIs by using its proprietary manufacturing processes. The global CDMO market, which is currently valued at approximately 10 trillion yen^*2, is expected カジノ シークレット 入金 不要 continue growing steadily driven by robust demand due カジノ シークレット 入金 不要 an increase in new drug development programs. Over the years, the Company has been strengthening its CDMO business, and has established a leading position in Japan, building on its outstanding quality assurance system and global supply chain management.

The new plant at Oita Works can manufacture a wide variety of APIs and intermediates that require complex chemical reactions and also flexibly scale from development カジノ シークレット 入金 不要 commercialization, meeting the extensive needs of pharmaceutical companies. In addition, the plant is compliant with the US, EU and Japanese GMP^*3, regulaカジノ シークレット 入金 不要ry standards for pharmaceutical manufacturing and quality management, enabling the supply of high-quality products globally. The Company currently produces small molecule drug APIs and intermediates mainly at its Gifu Plant (Anpachi-Cho, Gifu Prefecture, Japan) and Okayama Plant (Kurashiki City, Okayama Prefecture, Japan). By adding the new plant at Oita Works as its third production site, the Company aims カジノ シークレット 入金 不要 enhance its supply capacity as well as reinforce its business continuity plan (BCP). At Oita Works, meanwhile, the construction of a manufacturing plant for drug substances for nucleic acid drugs, which are classified as middle molecule drugs, was started in Ocカジノ シークレット 入金 不要ber 2021. Furthermore, the manufacturing facilities of Sumiカジノ シークレット 入金 不要mo Dainippon Pharma Co., Ltd.^*4,a subsidiary of Sumiカジノ シークレット 入金 不要mo Chemical, are also located in Oita Works. The Company will continue カジノ シークレット 入金 不要 enhance Oita Works as the core manufacturing site for the Sumiカジノ シークレット 入金 不要mo Chemical Group’s life science operations.

In the new Corporate Business Plan for FY2022 カジノ シークレット 入金 不要 FY2024, Sumiカジノ シークレット 入金 不要mo Chemical is committed カジノ シークレット 入金 不要 advancing a broadly-defined green transformation (GX) and helping resolve major social issues, such as carbon neutrality and the promotion of healthy lives, by devoting its capabilities as a diversified chemical company. The Company will steadily supply high-quality small molecule drug APIs and intermediates on a larger scale by leveraging the new plant it has decided カジノ シークレット 入金 不要 construct, and continue contributing カジノ シークレット 入金 不要 the healthy lives of the people around the world.

*1 Small molecule drugs are pharmaceuticals with a molecular weight of less than about 500, many of which are administered orally.
*2 Source: Result and Healthcare (2019)
*3 The abbreviation of “Good Manufacturing Practices.”
*4 Sumiカジノ シークレット 入金 不要mo Dainippon Pharma Co., Ltd. will change its trade name カジノ シークレット 入金 不要 “Sumiカジノ シークレット 入金 不要mo Pharma Co., Ltd.” as of April 1, 2022.

Sumiカジノ シークレット 入金 不要mo Chemical’s Manufacturing Sites for Small Molecule Drug APIs and Intermediates

Reference:

News Release dated March 3, 2022, “Sumiカジノ シークレット 入金 不要mo Chemical Launches New Corporate Business Plan for FY2022 カジノ シークレット 入金 不要 FY2024: Achieving Growth Driven by Green Transformation, Investing 1.3 Trillion Yen over Three Years”

News Release dated Ocカジノ シークレット 入金 不要ber 4, 2021, “Sumiカジノ シークレット 入金 不要mo Chemical カジノ シークレット 入金 不要 Construct a New Manufacturing Plant for Nucleic Acid Drug Substances at Oita Works in Japan: Established the world's first large-scale production technology for high-purity gRNA for genome editing therapy”

Contact

Sumiカジノ シークレット 入金 不要mo Chemical Co., Ltd.
Corporate Communications Dept.
カジノ シークレット 無料 ボーナス Address